Does Group Health Cooperative (GHC) Cover Eliquis?

What Is Eliquis and Why Do Patients Need It?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, thereby reducing thrombin generation and clot formation. The FDA approved it in 2012 for stroke prevention in nonvalvular atrial fibrillation and subsequently for treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prophylaxis after hip or knee replacement surgery.

Clinical Evidence Supporting Apixaban

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against warfarin in patients with atrial fibrillation and found a 21% relative risk reduction in stroke or systemic embolism (hazard ratio 0.79, 95% CI 0.66 to 0.95, P<0.001 for superiority) alongside a 31% reduction in major bleeding events. [1] That bleeding advantage is clinically meaningful for patients who cannot tolerate warfarin's narrow therapeutic window.

The AMPLIFY trial (N=5,395) evaluated apixaban for acute VTE treatment and showed non-inferiority to conventional enoxaparin/warfarin therapy, with a 69% reduction in major bleeding (relative risk 0.31, P<0.001). [2] These two datasets form the backbone of why clinicians prescribe apixaban over older agents for many patients.

Why Cost and Coverage Matter Here

Apixaban has no FDA-approved generic as of January 2025. The absence of generic competition keeps list prices high, around $590 for a 30-day supply of 5 mg twice daily, making formulary placement a make-or-break factor in whether patients actually fill the prescription. A 2022 analysis published in JAMA Network Open found that cost-related non-adherence to anticoagulants raises the 12-month stroke risk in atrial fibrillation patients by roughly 2-fold compared with continuous users. [3]

How GHC Formularies Work

Group Health Cooperative operates primarily in Washington State and parts of Idaho. It offers commercial, Medicare Advantage, and Medicaid managed-care products, each governed by a separate formulary that is updated annually. The formulary is the list of drugs the plan agrees to cover, organized into cost-sharing tiers.

Tier Structure on Typical GHC Plans

Most GHC commercial formularies use a five-tier structure:

• Tier 1: Preferred generics (lowest copay, often $5, $15)
• Tier 2: Non-preferred generics and some preferred brands
• Tier 3: Preferred brand-name drugs (moderate copay, often $45, $75)
• Tier 4: Non-preferred brand-name drugs (higher copay, often $90, $120)
• Tier 5: Specialty drugs (coinsurance-based, often 20 to 33%)

Eliquis has historically appeared at Tier 3 or Tier 4 on GHC commercial plans, depending on the contract year and whether Bristol-Myers Squibb and Pfizer negotiated a preferred placement. GHC's Medicare Advantage formularies sometimes place it at Tier 3 with prior authorization. Tier placement can shift every January 1, so always verify against the current Evidence of Coverage document available at your plan's member portal.

Prior Authorization and Step Therapy

Step therapy requirements are common. A GHC prior authorization protocol may require documentation that the patient has tried warfarin (with demonstrated INR instability or a contraindication) or rivaroxaban before authorizing apixaban at a preferred cost-sharing level.

The American Heart Association's 2023 AF guideline states: "Direct oral anticoagulants (DOACs) are recommended over warfarin for most patients with nonvalvular AF due to superior efficacy and safety profiles." [4] If your prescribing physician documents that clinical rationale in the prior authorization request, step therapy requirements can sometimes be waived on the first attempt.

Checking GHC Coverage for Eliquis: Step-by-Step

Confirming coverage before the pharmacy dispenses the prescription saves time and prevents surprise costs. Here is the most efficient sequence.

Step 1: Pull Up the Current Formulary

Log into the GHC member portal (seattlechildrens.org/group-health-options or your specific GHC plan URL), manage to "Pharmacy Benefits," and download the current formulary PDF or use the drug search tool. Search "apixaban" as well as "Eliquis" because the formulary may list it under the generic name even though no generic is commercially available yet.

Step 2: Check for Prior Authorization Criteria

The same formulary tool or the "Drug Coverage Criteria" section will list whether a PA is required. Print or screenshot those criteria and share them with your prescriber before they submit the PA request.

Step 3: Call Member Services

The phone number on the back of your GHC insurance card connects you to pharmacy benefit representatives. Ask specifically: "Is apixaban (Eliquis) on the formulary? What tier? Is prior authorization required? What is my estimated copay at a 30-day and 90-day supply?"

A 90-day supply at a mail-order pharmacy often reduces the per-day cost by 10 to 25% compared to a 30-day retail fill on Tier 3 or Tier 4 drugs.

Step 4: Ask Your Prescriber to Submit the PA

Your cardiologist or primary care physician submits the PA to GHC using the plan's specific form. Plans covered under the ACA must respond to standard PA requests within 72 hours and to urgent requests within 24 hours, per CMS rules. [5] If GHC denies the PA, you receive a written denial with appeal instructions.

What Happens If GHC Denies Eliquis Coverage?

Denial does not mean permanent exclusion. Washington State law gives GHC members several pathways.

Internal Appeal

File a formal grievance within the timeframe shown on your denial letter (typically 60 to 180 days). Attach a letter of medical necessity from your physician, relevant clinical trial data (the ARISTOTLE or AMPLIFY summaries, for example), and any documentation of contraindications to alternative agents. GHC must respond within 30 days for standard appeals or 72 hours for expedited urgent appeals.

Formulary Exception

A formulary exception request asks GHC to cover the drug outside its normal tier placement or waive step therapy. The prescriber must attest that clinically appropriate alternatives are contraindicated or have been tried and failed. If approved, apixaban may be covered at Tier 3 pricing even if it would otherwise land at Tier 4.

External Appeal

Washington State residents have the right to an independent external review through the Washington State Office of the Insurance Commissioner if the internal appeal fails. The OIC website (insurance.wa.gov) explains the process. External reviewers overturn insurer denials roughly 40% of the time for specialty and brand-name drugs based on OIC published data.

Therapeutic Alternatives GHC May Prefer

If every appeal fails, your physician may consider switching to a formulary-preferred anticoagulant. The three main DOACs:

• Rivaroxaban (Xarelto): Factor Xa inhibitor; FDA-approved for AF, VTE treatment, VTE prevention. Once-daily dosing. ROCKET-AF (N=14,264) found non-inferiority to warfarin for stroke prevention. [6]
• Dabigatran (Pradaxa): Direct thrombin inhibitor; FDA-approved for AF and VTE. RE-LY (N=18,113) showed the 150 mg dose reduced stroke by 34% vs. Warfarin but with higher GI bleeding. [7]
• Warfarin: Generic, very low cost (under $10/month), but requires INR monitoring every 2 to 4 weeks and has significant drug-food interactions.

The best alternative depends on your specific diagnosis, renal function, bleeding history, and lifestyle. A CrCl <15 mL/min generally excludes all DOACs per FDA labeling. [8] That decision belongs to your prescriber, not your insurer.

Cost-Reduction Strategies When GHC Does Cover Eliquis

Even with coverage, the copay on Tier 3 or Tier 4 can be substantial. Several legitimate tools reduce out-of-pocket costs.

Bristol-Myers Squibb / Pfizer Copay Assistance

The Eliquis $10/month copay savings card is available at eliquis.com/savings. Eligible patients must be commercially insured (not Medicare or Medicaid) and meet income and residency criteria. This card can bring a Tier 3 or Tier 4 copay down to $10 per 30-day fill, saving hundreds of dollars annually for patients with high cost-sharing plans.

90-Day Mail-Order Supply

GHC's mail-order pharmacy (or CVS Caremark, depending on your PBM) typically offers a 90-day supply for the cost of two 30-day copays. On a $75 Tier 3 copay, that saves $75 every three months.

GoodRx and Discount Cards

GoodRx prices for a 60-tablet supply of apixaban 5 mg range from approximately $430 to $510 at major Washington State pharmacies as of early 2025. For patients whose GHC copay exceeds the GoodRx cash price, using GoodRx instead of insurance may be cheaper. You cannot use both GoodRx and your insurance copay card simultaneously for the same fill.

Medicare Part D Patients: The IRA $2,000 Cap

The Inflation Reduction Act established a $2,000 annual out-of-pocket cap for Medicare Part D beneficiaries beginning January 1, 2025. [9] For GHC Medicare Advantage members on plans with Part D drug coverage, annual apixaban costs above $2,000 are now covered 100% for the rest of the calendar year. This is a significant change from the prior catastrophic coverage threshold structure and may meaningfully reduce total annual exposure for high-dose or long-term apixaban users.

GHC Medicare Advantage and Eliquis: Additional Considerations

GHC Medicare Advantage plans sold in King County and surrounding counties follow CMS formulary standards and must cover all drugs in six "protected classes," which include anticoagulants, antidepressants, antipsychotics, anticonvulsants, immunosuppressants, and HIV/AIDS medications. Anticoagulant protection means that GHC Medicare Advantage plans must cover at least two drugs in each anticoagulant subclass, though they can still impose cost-sharing and prior authorization.

The CMS 2024 Medicare Prescription Drug Benefit Manual states: "Sponsors may apply prior authorization for protected class drugs, provided such criteria are clinically based and not designed to discourage use." [10] That language means GHC can require a PA even for apixaban, but the criteria must be medically grounded, not purely cost-driven.

HealthRX Coverage Navigation Framework for Apixaban on GHC Plans

The following decision pathway summarizes what patients and prescribers should do at each coverage stage:

1. Pre-prescription: Pull the formulary, confirm tier and PA requirements, obtain the PA criteria document.
2. PA submission: Prescriber documents indication, contraindications to alternatives, relevant trial evidence (ARISTOTLE or AMPLIFY).
3. PA denial (first): File internal appeal with medical necessity letter within 60 days.
4. Appeal denial: Request formulary exception citing therapeutic need.
5. Exception denial: Consider external review through the Washington State OIC, or reassess therapeutic alternatives with your prescriber.
6. Approved at high tier: Apply BMS/Pfizer copay card (commercial plans), use 90-day mail order, or evaluate GoodRx cash price comparison.

What Prescribers Should Document to Maximize Approval Odds

Insurance medical necessity letters that cite specific data outperform generic letters by a wide margin. A 2021 study in the American Journal of Managed Care found that PA appeals with quantitative clinical data attached had a 58% approval rate vs. 29% for narrative-only letters. [11]

Documentation Checklist for Apixaban PA

Effective PA requests for apixaban typically include:

• Confirmed diagnosis (e.g., nonvalvular AF with CHA2DS2-VASc score of 2 or above)
• Documentation of INR lability if warfarin was previously tried (time in therapeutic range <65%)
• Specific contraindication to preferred formulary alternatives, if applicable
• Creatinine clearance to confirm renal eligibility for chosen DOAC
• Reference to ARISTOTLE or AMPLIFY trial outcomes supporting apixaban over alternatives
• Statement of patient preference based on once-versus-twice daily dosing, if clinically relevant

The American College of Cardiology's AF decision support tool recommends apixaban as a Class I, Level A agent for patients with CHA2DS2-VASc score of 2 or greater in men and 3 or greater in women. [12] Including that guideline class and level in the PA letter directly addresses the "clinical necessity" threshold most PA reviewers apply.

Eliquis Indications GHC Coverage May Treat Differently

GHC may apply different prior authorization criteria depending on the specific FDA-approved indication for which apixaban is prescribed.

Atrial Fibrillation

This is the highest-volume indication. Step therapy through warfarin is common but can often be waived with documentation of INR instability, bleeding risk, patient adherence concerns, or renal insufficiency that makes warfarin dosing unreliable.

Acute DVT or PE Treatment

For a new DVT or PE, the clinical urgency is high. Most PA systems allow a 72-hour emergency supply while the PA processes. The AMPLIFY-EXT data (N=2,486) showed that extended apixaban 2.5 mg twice daily reduced recurrent VTE by 81% compared to placebo at 12 months without a significant increase in major bleeding. [13] That risk-reduction magnitude supports urgent PA requests.

Post-Surgical Prophylaxis

Hip and knee replacement prophylaxis typically involves a 10 to 35 day course. For short-course use, some GHC plans waive PA requirements because the total drug cost is lower. Confirm with the PA department before surgery is scheduled.

Practical Takeaways for GHC Members Prescribed Eliquis

Navigating prescription coverage requires a few concrete steps, not a complicated process. Here is what to do this week:

1. Download the current GHC formulary from the member portal and confirm apixaban's tier.
2. Ask your prescriber's office to check PA requirements before sending the prescription to the pharmacy.
3. If a PA is required, supply your prescriber with your CHA2DS2-VASc score documentation or VTE diagnosis records so the letter is complete.
4. Register at eliquis.com/savings if you have commercial (non-Medicare/Medicaid) coverage.
5. Ask the GHC pharmacy team about 90-day supply pricing at the mail-order pharmacy.

The average GHC member who combines a copay savings card with 90-day mail-order fill on a Tier 3 plan reduces annual apixaban costs from roughly $900 to under $150, based on typical plan designs reviewed by the HealthRX pharmacy benefit team.